The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT).

Start Date13 May 2022

Sponsor / Collaborator

Bausch & Lomb, Inc.

NCT03931317 / CompletedNot ApplicableIIT

A Randomized, Single Center, Masked, Crossover Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity in Patients With Ocular Hypertension or Primary Open Angle Glaucoma

The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.

Start Date03 Dec 2018

Sponsor / Collaborator

University of California San Diego

[+1]

NCT01895972 / CompletedPhase 3

A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension

The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.

Start Date05 Jul 2013

Sponsor / Collaborator

Bausch & Lomb, Inc.

100 Clinical Results associated with Latanoprostene Bunod

100 Translational Medicine associated with Latanoprostene Bunod

100 Patents (Medical) associated with Latanoprostene Bunod

Literatures (Medical) associated with Latanoprostene Bunod

01 Feb 2024·Current Opinion in Pharmacology

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review

Review

Author: Anter, Abdelrahman M ; Benitez, Betsy ; Bhattacharya, Sanjoy K ; Arcuri, Jennifer

Recent advancements in prostaglandin analogs (PGAs) have reinforced their role in managing intraocular pressure (IOP). Latanoprost excels in 24-h IOP control, while various PGAs offer similar effectiveness and side effects, generic PGAs perform as well as branded ones, and a notable IOP rise observed upon PGA discontinuation. Formulations with or without preservatives show comparable IOP reduction and adherence, often surpassing benzalkonium chloride (BAK)-preserved options. Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments.

17 Jan 2024·Journal of Current Glaucoma Practice

Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%

Article

Author: Logioco, Celina ; Zanutigh, Virginia ; Galetto, Leila ; Valvecchia, Florencia

Aim and backgroundTo evaluate the ocular surface of patients treated with latanoprost (LT) 0.005% who switched to latanoprostene bunod (LBN) 0.024%.Materials and methodsA prospective and nonrandomized clinical study of a case series was performed, including patients with chronic open-angle glaucoma who were on previous LT-only treatment and, after a washout period, switched to LBN, with a 3-month follow-up. The main parameter to be evaluated was the ocular surface disease index (OSDI) test. In addition, best-corrected visual acuity (BCVA), intraocular pressure (IOP), biomicroscopic aspect of the ocular surface, measuring tear breakup time, fluorescein staining (grading performed on Oxford scale) and Schirmer I test were evaluated.ResultsA total of 36 patients (72 eyes) were included, 21 women (58.3%) and 15 men (41.7%, with a mean age of 65.6 ± 10.9 years (37-86). The initial OSDI score was 17.8 ± 12.1 and improved to 11.1 ± 10.5 (p < 0.01). From the data evaluated at biomicroscopy, an improvement was observed in the Oxford scale from 0.6 ± 0.7 to 0.2 ± 0.8 (p: 0.01), but no statistically significant changes were observed in the break-up time (BUT) and Schirmer. BCVA remained stable, as did IOP, which was initially 13.4 ± 2.1 mm Hg and, after performing the LBN treatment change, went to 13.1 ± 1.7 mm Hg.ConclusionAfter the change of treatment from LT 0.005% to LBN 0.024%, the patients had an improvement in the ocular surface, maintaining control of their IOP. The need to investigate possible beneficial mechanisms on the ocular surface in glaucoma patients treated with LBN, potentially related to nitric oxide, is raised.Clinical significancePatients treated with LT 0.005% who switched to LBN 0.024% had an improvement in ocular surface symptoms and signs, keeping IOP under control.Latanoprostene bunod (LBN) 0.024% may have beneficial effects on the ocular surface, which should be further studied.How to cite this articleZanutigh V, Galetto L, Valvecchia F, et al. Ocular Surface Evaluation after Switch from Latanoprost 0.005% to Latanoprostene Bunod 0.024%. J Curr Glaucoma Pract 2023;17(4):205-209.

01 Jan 2024·Journal of Cataract and Refractive Surgery

Difficult decisions, filtration surgery, and the heartbreak of the numerator

Article

Author: Brubaker, Jacob W ; Barton, Keith ; Brubaker, Jacob W. ; Grover, Davinder S ; Ahmed, Iqbal Ike K. ; Gedde, Steven J ; Zhang, Amy D ; Zhang, Amy D. ; Samuelson, Thomas W. ; Paranjpe, Vikram R. ; Paranjpe, Vikram R ; Singh, Kuldev ; De Francesco, Ticiana ; Grover, Davinder S. ; Gedde, Steven J. ; Fellman, Ronald L. ; Ahmed, Iqbal Ike K ; Fellman, Ronald L

A 70-year-old man had progressive and severe glaucoma in each eye. He was intolerant to dorzolamide, brimonidine, and netarsudil. Each eye had prior selective laser trabeculoplasty (SLT) as well as phacoemulsification plus minimally invasive glaucoma surgery (MIGS) 6 years before current presentation (iStent [Glaukos Corp.] in the right eye and Cypass [Alcon Laboratories, Inc.] in the left eye). Postoperative acuities were 20/20 and 20/25 in the right and left eyes, respectively.When his left eye progressed with loss of central acuity despite peak intraocular pressures (IOPs) in the middle to upper teens, neuro-ophthalmology consultation was obtained (Figure 1 JOURNAL/jcrs/04.03/02158034-202401000-00017/figure1/v/2023-12-22T124801Z/r/image-tiff ). That workup included magnetic resonance imaging scan and hematologic screening, but all results were negative, and the neuro-ophthalmic consultant concluded that the vision loss was likely on the basis of glaucoma. Accordingly, a trabeculectomy was performed in the left eye achieving consistent IOPs in the range of 7 to 10 mm Hg without medications, rending the left eye stable since the filtration surgery nearly 2 years previously.The right eye continued to progress both subjectively and objectively, and on recent examination, the IOP measured 20 mm Hg and 09 mm Hg in the right and left eyes, respectively (Figure 2 JOURNAL/jcrs/04.03/02158034-202401000-00017/figure2/v/2023-12-22T124801Z/r/image-tiff ). Medications included timolol and latanoprostene bunod in the right eye only. Central corneal thickness was 526 μm and 527 μm in the right and left eyes, respectively. The visual acuity now measured 20/25 in the right eye and 20/250 in the left eye. The vertical cup-to-disc ratio was 0.9 in the right eye and 1.0 in the left eye. Gonioscopy revealed a wide open angle in each eye with a patent sclerostomy superiorly in the left eye. The conjunctiva and sclera were healthy and without scarring in the right eye. The bleb in the left eye was diffuse, lightly vascularized, and seidel negative. Axial length (AL) was 26.88 μm in the right eye and 26.77 μm in the left eye. The patient was in good health and was not anticoagulated.An extensive discussion ensued about the best course of action for the right eye.How would you proceed in managing definite progression in this individual's right eye, knowing that he had lost fixation in his left eye at similar pressures?

News (Medical) associated with Latanoprostene Bunod

17 Oct 2024

·www.globenewswire.com

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024The Company estimates that it is financed into Q3 2025 October 17, 2024 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position for Nicox SA and its subsidiaries (the “Nicox Group”) for the third quarter of 2024 and financial results for Nicox SA (the “Company”) for the first half of 2024, as approved by the Board of Directors on October 16, 2024 and provided an update on key future milestones. As previously announced, the Company is no longer reporting consolidated accounts under IFRS standards and figures communicated for the Nicox Group are for information only. “The first 9 months of 2024 have been a period of significant strategic progress for Nicox, in which we have stabilized our financial situation with a royalty sale, optimised our cost structure to focus on our lead asset and partnerships, renewed the Board of Directors and increased our institutional shareholder base through targeted financing activities. Our development team has also continued driving the NCX 470 Denali clinical trial with the completion of recruitment in the United States in July, and the target date for topline results now advanced to Q3 2025.” said Gavin Spencer, Chief Executive Officer of Nicox. “We have also seen major progress in our partnership activity, with our Chinese licensee Ocumension Therapeutics obtaining approval for ZERVIATE in China, where we are now awaiting the commercial launch, and the signature of a new research agreement, including a pre-agreed license option, for NCX 1728 with leading ophthalmic pharmaceutical and medical technology company Glaukos. Going forward we will be focussing on the completion of the Denali trial and partnerships for the commercialisation of NCX 470 in the United States and elsewhere.” Key Future Milestones Launch of ZERVIATE in China by Nicox’s partner, Ocumension Therapeutics: Approval obtained in September 2024. Whistler Phase 3b clinical trial, initiated in December 2023, investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: results are currently expected in the first quarter of 2025. Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: recruitment of the last patient in the U.S. in the Denali trial was in July when overall recruitment was approaching the 95% level, with recruitment continuing in China and topline results are expected in Q3 2025. Management ChangeEmmet Purtill, Vice President of Business Development at Nicox, has joined the Executive Committee. Emmet has been with the company since 2006 and has played a significant role in establishing our partnerships, notably the relationships with Ocumension and Kowa, and had led many of our recent deals. Emmet joins Sandrine Gestin, VP Finance and HR, Doug Hubatsch, Chief Scientific Officer and Gavin Spencer, Chief Executive Officer, who are the other Executive Committee members.Revenue, Cash Position for the Nicox Group for the Third Quarter 2024 and post-period events Due to the sale of the VYZULTA royalty, the Nicox Group received no material revenue in the third quarter of 2024 compared to €1.8 million (net revenue1 €1.1 million, entirely composed of net royalties) for the first quarter 2023.$16.5 million Royalty and Equity Financing with Soleus announced on October 14, 2024.Cash of €19.7 million at 30 September 2024 including the estimated net proceeds from the VYZULTA royalty sale and accompanying investment mentioned above, after deduction of legal, banking and other fees, compared to €7.7 million at 30 June 2024. Based on this cash position, expected milestone income from existing agreements, and accounting for the €5.2 million debt repayments by June 2025, the Company estimates that it is financed into Q3 2025. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company. The Company cannot guarantee that it is financed to the topline results of the Denali trial, and completion of the Denali clinical trial may require additional financing.As of September 30, 2024, the Nicox Group had financial debt of €20.4 million (entirely held by Nicox SA), consisting of €19.4 million in the form of a bond financing agreement with Kreos Capital (an affiliate of BlackRock), and a €1.0 million credit agreement guaranteed by the French State, and granted in the context of the COVID-19 pandemic. Nicox will be repaying €5.2 million of the Kreos Capital debt by June 2025.The Company continues to evaluate all options for non-dilutive and dilutive financing to extend its cash runway. In particular the Company is actively exploring multiple strategic options which could facilitate the development and commercialization of its product candidate NCX 470 and the future growth of the Company. First Half 2024 Financial Results for Nicox SA Net revenue1 for the first half of 2024 was €4.9 million (including €1.7 million of net royalty payments and a license payment of €3.0 million) versus €1.7 million (consisting entirely of net royalty payments) for the first half of 2023. Operating expenses for the first half of 2024 were €10.1 million compared to €14.8 million for the first half of 2023. The decrease in operating expenses for the first half of 2024 compared with the first half of 2023 is explained by the costs related to the finalization of the Mont-Blanc study which had an impact on the first half of 2023. In addition, operating expenses for the first half of 2023 included a €3.5 million adjustment relating to the rebilling of services performed in 2022 by the U.S. subsidiary.Net loss for the six months ended June 30, 2024, was €4.4 million, compared to a net loss of €12.5 million for the same period in 2023. The reduction in the net loss for the first half of 2024 is mainly due to the increase in revenues following the signature of the agreement with Kowa for Japan for which the Company has received an initial payment of €3 million, and to the reduction in operating expenses as explained above.As of June 30, 2024, Nicox SA had cash and cash equivalents of €7.7 million as compared with €11.3 million as of December 31, 2023. Including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024 and exclusively on the basis of the development of NCX 470, the Company estimates it is currently funded into Q3 2025. As of June 30, 2024, Nicox SA had financial debt of €20.5 million, consisting of (i) €19.4 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and (ii) a €1.1 million credit agreement guaranteed by the French State, and granted in August 2020 in the context of the COVID-19 pandemic.Only the figure related to the cash position and the debt of Nicox SA as of December 31, 2023, is audited; all other figures in this press release are non-audited. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. . Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Income Statement (in thousands of euros) June 30, 2024June 30, 2023Sales of services – Various re-invoicing 23Royalties for patent grants 6 0672 721REVENUE 6 0692 724Reversals of depreciation, amortization, provisions and transfers of expenses 4497Other income 10577TOTAL OPERATING INCOME 6 6232 807Other purchases and external charges (6 853)(12 049)Taxes, duties and similar payments (42)(63)Salaries and wages (1 548)(918)Social security expenses (412)(361)Amortization (9)(11)Provisions for liability and charges -(108)Other expenses (1 190)(1 189)Exchange loss on receivables and debts (57)(130)TOTAL OPERATING EXPENSES (10 111)(14 829) OPERATING PROFIT (LOSS) (3 488)(12 022)Other interest and similar income 398550Reversal of provisions, impairment losses and transfer of expenses 1339Foreign exchange gains 23110TOTAL FINANCIAL INCOME 434699Amortization, depreciation and financial provisions (311)(306)Interest and similar expenses (789)(790)Foreign exchange loss -(212)Interests on loan (28)(29)Net expense from sales of investments securities (72)(185)TOTAL FINANCIAL EXPENSES (1 200)(1 522) FINANCIAL PROFIT (LOSS) (766)(823) PRE-TAX LOSS (4 254)(12 845)Exceptional income on management operations 3-Exceptional income from previous financial year -63EXCEPTIONAL INCOME 363 EXCEPTIONAL INCOME (LOSS) (23)63Research tax credit -251NET PROFIT & LOSS (4 277)(12 531) Balance sheet June 30, 2024December 31, 2023(in thousands of euros) ASSETS Intangible fixed assets1824Tangible fixed assets1426Financial fixed assets1 7291 805 FIXED ASSETS1 7611 855 Trade receivables and related accounts3 0223 424Other receivables (1)34 98434 324Cash assets7 65411 259Prepaid expenses1 207886 CURRENT ASSETS46 86749 893 Unrealized foreign exchange losses and valuation differences – Assets713Loan redemption premiums9141 218 TOTAL REGULARISATION ACCOUNTS9211 231 TOTAL ASSETS49 54952 979 LIABILITIES Share Capital63550 170Premiums related to share capital532 068529 478Retained earnings(508 438)(537 354)Net loss for the financial year(4 277)(20 881) Total shareholders' equity19 98821 413 Provisions for liabilities713Provisions for charges256700 Total provisions for liabilities and charges263713 Loans and debts from lending institutions20 53620 895Loans and other financial debts3 1564 258Accounts payable and related accounts1 5802 498Tax and social security debts515648Deferred income1 9951 919 Total current liabilities27 78230 218 Unrealized exchange gains1 516635 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY49 54952 979 1 Net revenue consists of revenue from collaborations less royalty payments Attachment EN_H1&Q32024_PR_FINAL

License out/inPhase 3Financial Statement

14 Oct 2024

·endpts.com

Bausch + Lomb's stock rises following report of potential bid from private equity firms TPG and Blackstone

Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + Lomb, the Financial Times reports. Citing “people familiar with the matter,” FT wrote Monday that the groups had already expressed interest in buying Bausch + Lomb before it was publicly listed in 2022. Its stock $BLCO rose about 9% on Monday following the reporting, trading around $21. Incoming offers for the company are expected to value it at an enterprise value between $13 billion and $14 billion, FT reports, with formal offers expected by as early as the end of October, though “several” other private equity firms considering making an offer have dropped out of the race. FT added that the sale process for the company is led by advisors at Goldman Sachs and started in order to resolve a feud between shareholders and creditors of its parent company Bausch Health, which is also a majority owner. Representatives for Bausch, Blackstone and TPG all declined to comment to Endpoints News , with Bausch adding that it doesn’t comment on “rumors or speculation.” Bausch + Lomb is known for its vision care products like contact lenses and eye drops, including its glaucoma drugs Vyzulta, Timoptic and Istalol. The company recorded $1.2 billion in revenue for the second quarter of 2024, a 17% increase from the same quarter last year.

Acquisition

14 Oct 2024

·endpts.com

Akeso raises $250M; SalioGen’s layoffs

Plus, news about Nicox, Soleus and Molecular Templates: Akeso Biopharma’s $250M placement: The Hong Kong-based company, which is developing a closely watched bispecific antibody with Summit Therapeutics, now has $1.06 billion in cash on hand. — Jaimy Lee SalioGen’s layoffs: Several employees posted on LinkedIn about layoffs at the Lexington, MA-based gene coding startup, though a SalioGen spokesperson declined to comment. The company this summer talked about plans to take its gene insertion platform into the clinic by the middle of 2025 for Stargardt disease. It last disclosed a $115 million Series B in January 2022. Two months ago, another gene insertion startup, Tome Biosciences, disclosed it let go of almost all of its employees . — Kyle LaHucik Nicox, Soleus ink royalty and equity deal: The life sciences investor is acquiring the royalty to Vyzulta, a prescription eye drop, for $15 million, net of payments to Pfizer. It’s also investing $1.5 million in Nicox shares. Nicox now has runway into the third quarter of next year. — Jaimy Lee Molecular Templates may wind down its business after failing to secure “strategic alternatives,” according to a securities filing. It is also laying off most of its workers and shutting down Phase 1 studies of two assets: MT-6402 and MT-8421. It had 62 full-time employees, as of Dec. 31. — Jaimy Lee

Gene TherapyPhase 1Acquisition

100 Deals associated with Latanoprostene Bunod

External Link

KEGG	Wiki	ATC	Drug Bank
D10441	Latanoprostene Bunod	S01EE06	DB11660

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ocular Hypertension	JO	Bausch & Lomb, Inc.	04 Aug 2021
Glaucoma	UA	Bausch & Lomb, Inc.	09 Sep 2020
Glaucoma, Open-Angle	US	Bausch & Lomb, Inc.	02 Nov 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Discovery	JP	Bausch & Lomb, Inc.	01 Dec 2007
Glaucoma 1, Open Angle, A	Discovery	US	Bausch & Lomb, Inc.	01 Mar 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03931317 (Pubmed \| Am J Ophthalmol) Manual	Not Applicable	Glaucoma, Open-Angle \| Ocular Hypertension	50	Latanoprostene Bunod	ztbotnzpoj(ivhcxszcuf) = atckayyymp wuciylobqe (mwbfbdazto )	Positive	05 May 2022
				Timolol	-
ARVO2022	Not Applicable	-	-	Latanoprostene bunod ophthalmic solution	(ijscnhbksc) = Both latanoprostene bunod and latanoprost administration resulted in mild to moderate conjunctival hyperemia ybtaqyaybr (qohmlpxzpi )	Positive	01 May 2022
ARVO2022	Not Applicable	Glaucoma, Open-Angle	65	Vyzulta	(kyfigbqtyw) = solwmpszan fzoqrjishy (onnvvdalph )	-	01 May 2022
				Latanoprost	(kyfigbqtyw) = liblxtfrln fzoqrjishy (onnvvdalph )
ARVO Annual Meeting (ARVO2021)	Not Applicable	Glaucoma	36	Latanoprostene bunod	(tmrpehfkof) = okrprrrdzc waosnnjjiu (ffwesnwdzy ) View more	Positive	01 Jun 2021
AAO2020	Not Applicable	-	80	Latanoprostene Bunod	(zhlavaaaky) = Four patients discontinued for adverse effects rjkhxrsrij (czyzkjxvam )	-	13 Nov 2020
NCT00441883 (CTgov)	Phase 2	Glaucoma 1, Open Angle, A	176	PF-03187207 (PF-03187207 0.024% AM)	ijuelapoun(dpuzwmbyof) = seedtvlnmp trthypmwhu (ghepgunlbm, wmtgrrnejc - mzmodmyzpd) View more	-	27 Aug 2020
				PF-03187207 (PF-03187207 0.040% AM)	ijuelapoun(dpuzwmbyof) = qsnoygxncm trthypmwhu (ghepgunlbm, vstyslmuja - virzdotpvz) View more
NCT00595101 (CTgov)	Phase 2	Glaucoma, Open-Angle	117	PF-0318 (PF-0318 0.006%)	njfjgoyepw(etohloqldj) = teieslzkrx zqdmspiocp (wjkpqwpdrv, bheotlpuga - wzgenxjcju) View more	-	27 Aug 2020
				PF-0318 (PF-0318 0.024%)	njfjgoyepw(etohloqldj) = pweimnfhyo zqdmspiocp (wjkpqwpdrv, esmclmrzfd - yljytrkkbc) View more
2019 ARVO Annual Meeting (ARVO2019)	Not Applicable	Glaucoma, Open-Angle	11	Latanoprostene bunod	(zkyjvrrcuv) = tktmiybdtc wafsirsdxd (nqoaeccjbc, ± 447)	Positive	01 Jul 2019
NCT01749930 (LUNAR, CTgov)	Phase 3	Glaucoma, Open-Angle	420	BOL-303259-X (BOL-303259-X)	yvouaaszsv(jxrxqfcrrc) = skjeniownt mkljchfhnq (jrbdiktfza, phahsfjsii - xtyozezmgs) View more	-	21 Nov 2018
				Timolol+BOL-303259-X (Timolol)	yvouaaszsv(jxrxqfcrrc) = bilefpxzww mkljchfhnq (jrbdiktfza, brlyxefgqu - lafvwgtxts) View more
NCT01749904 (APOLLO, CTgov)	Phase 3	Glaucoma, Open-Angle	420	BOL-303259-X (BOL-303259-X)	vihwlmgony(hpnbrpoycb) = mopjgqlszh rwzbvoqlvb (lhwtxpogfo, xyxgrcmxrd - rstvrcapno) View more	-	07 Nov 2018
				Timolol+BOL-303259-X (Timolol)	vihwlmgony(hpnbrpoycb) = nnbqoxrixv rwzbvoqlvb (lhwtxpogfo, zwrzwrvtzg - jzdpuvakwf) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis